These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21034597)

  • 1. No-reflow protection and long-term efficacy for acute myocardial infarction with Tongxinluo: a randomized double-blind placebo-controlled multicenter clinical trial (ENLEAT Trial).
    Zhang HT; Jia ZH; Zhang J; Ye ZK; Yang WX; Tian YQ; Jia X; Li W; Wu YL; Yang YJ
    Chin Med J (Engl); 2010 Oct; 123(20):2858-64. PubMed ID: 21034597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracoronary nitroprusside for the prevention of the no-reflow phenomenon after primary percutaneous coronary intervention in acute myocardial infarction. A randomized, double-blind, placebo-controlled clinical trial.
    Amit G; Cafri C; Yaroslavtsev S; Fuchs S; Paltiel O; Abu-Ful A; Weinstein JM; Wolak A; Ilia R; Zahger D
    Am Heart J; 2006 Nov; 152(5):887.e9-14. PubMed ID: 17070151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial).
    Marso SP; Miller T; Rutherford BD; Gibbons RJ; Qureshi M; Kalynych A; Turco M; Schultheiss HP; Mehran R; Krucoff MW; Lansky AJ; Stone GW
    Am J Cardiol; 2007 Jul; 100(2):206-10. PubMed ID: 17631071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intravenous Elinogrel before PCI to optimize reperfusion in acute Myocardial Infarction (ERASE MI) pilot trial.
    Berger JS; Roe MT; Gibson CM; Kilaru R; Green CL; Melton L; Blankenship JD; Metzger DC; Granger CB; Gretler DD; Grines CL; Huber K; Zeymer U; Buszman P; Harrington RA; Armstrong PW
    Am Heart J; 2009 Dec; 158(6):998-1004.e1. PubMed ID: 19958867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial.
    Engelmann MG; Theiss HD; Hennig-Theiss C; Huber A; Wintersperger BJ; Werle-Ruedinger AE; Schoenberg SO; Steinbeck G; Franz WM
    J Am Coll Cardiol; 2006 Oct; 48(8):1712-21. PubMed ID: 17045910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergency percutaneous coronary intervention (PCI) for the care of patients with ST-elevation myocardial infarction (STEMI).
    Morrison DA; Berman M; El-Amin O; McLaughlin RT; Bates ER
    Minerva Cardioangiol; 2007 Oct; 55(5):593-623. PubMed ID: 17912165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE).
    Jang IK; Weissman NJ; Picard MH; Zile MR; Pettigrew V; Shen S; Tatsuno J; Hibberd MG; Tzivoni D; Wackers FJ;
    Am Heart J; 2008 Jan; 155(1):113.e1-8. PubMed ID: 18082500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of contrast-enhanced CMR early after acute ST segment elevation myocardial infarction (STEMI) in a regional STEMI network: results of the "Herzinfarktverbund Essen".
    Bruder O; Breuckmann F; Jensen C; Jochims M; Naber CK; Barkhausen J; Erbel R; Sabin GV;
    Herz; 2008 Mar; 33(2):136-42. PubMed ID: 18344033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between thrombolysis in myocardial infarction myocardial perfusion grade, biomarkers, and clinical outcomes among patients with moderate- to high-risk acute coronary syndromes: observations from the randomized trial to evaluate the relative PROTECTion against post-PCI microvascular dysfunction and post-PCI ischemia among antiplatelet and antithrombotic agents-Thrombolysis In Myocardial Infarction 30 (PROTECT-TIMI 30).
    Gibson CM; Kirtane AJ; Morrow DA; Palabrica TM; Murphy SA; Stone PH; Scirica BM; Jennings LK; Herrmann HC; Cohen DJ; McCabe CH; Braunwald E;
    Am Heart J; 2006 Oct; 152(4):756-61. PubMed ID: 16996854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. China Tongxinluo Study for myocardial protection in patients with Acute Myocardial Infarction (CTS-AMI): Rationale and design of a randomized, double-blind, placebo-controlled, multicenter clinical trial.
    Xu Y; Li X; Zhang H; Wu Y; Zhang J; Li J; Dou K; Yan H; You S; Yang Y; Liang Y; Xu L; Gao X; Liu C; Dong Q; Zhang W; Song G; Zhang T; Jiang L; Chen G; Tang R; Jin C; Yang J; Yao C; Xian Y; Peterson ED; Gao R; Yang Y
    Am Heart J; 2020 Sep; 227():47-55. PubMed ID: 32679281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-elevation myocardial infarction: a randomized, controlled trial.
    Kaltoft A; Bøttcher M; Nielsen SS; Hansen HH; Terkelsen C; Maeng M; Kristensen J; Thuesen L; Krusell LR; Kristensen SD; Andersen HR; Lassen JF; Rasmussen K; Rehling M; Nielsen TT; Bøtker HE
    Circulation; 2006 Jul; 114(1):40-7. PubMed ID: 16801464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction.
    Tartan Z; Ozer N; Uyarel H; Akgul O; Gul M; Cetin M; Kasikcioglu H; Cam N
    Nutr Metab Cardiovasc Dis; 2008 Jul; 18(6):441-7. PubMed ID: 17981019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheolytic thrombectomy with percutaneous coronary intervention for infarct size reduction in acute myocardial infarction: 30-day results from a multicenter randomized study.
    Ali A; Cox D; Dib N; Brodie B; Berman D; Gupta N; Browne K; Iwaoka R; Azrin M; Stapleton D; Setum C; Popma J;
    J Am Coll Cardiol; 2006 Jul; 48(2):244-52. PubMed ID: 16843170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stem cells mobilization in acute myocardial infarction (stem-AMI trial): preliminary data of a perspective, randomized, single blind trial.
    Malafronte C; Achilli F
    Minerva Cardioangiol; 2007 Dec; 55(6):721-31. PubMed ID: 18091641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limitations of using a GuardWire temporary occlusion and aspiration system in patients with acute myocardial infarction: multicenter investigation of coronary artery protection with a distal occlusion device in acute myocardial infarction (MICADO).
    Matsuo A; Inoue N; Suzuki K; Nakamura R; Fujita H; Miki S; Yokoi Y
    J Invasive Cardiol; 2007 Mar; 19(3):132-8. PubMed ID: 17341781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction: result of the double-blind, randomized, placebo-controlled stem cells in myocardial infarction (STEMMI) trial.
    Ripa RS; Jørgensen E; Wang Y; Thune JJ; Nilsson JC; Søndergaard L; Johnsen HE; Køber L; Grande P; Kastrup J
    Circulation; 2006 Apr; 113(16):1983-92. PubMed ID: 16531621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging.
    Eitel I; Nowak M; Stehl C; Adams V; Fuernau G; Hildebrand L; Desch S; Schuler G; Thiele H
    Am Heart J; 2010 May; 159(5):882-90. PubMed ID: 20435200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
    Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
    Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.
    Heestermans AA; Van Werkum JW; Hamm C; Dill T; Gosselink AT; De Boer MJ; Van Houwelingen G; Hoorntje JC; Koopmans PC; Ten Berg JM; Van 't Hof AW
    J Thromb Haemost; 2009 Oct; 7(10):1612-8. PubMed ID: 19682233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy.
    Mega JL; Morrow DA; De Lemos JA; Sabatine MS; Murphy SA; Rifai N; Gibson CM; Antman EM; Braunwald E
    J Am Coll Cardiol; 2004 Jul; 44(2):335-9. PubMed ID: 15261928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.